ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

Bookmark and Share
Published: 15 Dec 2020
Views: 3461
Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eric Smith

Dr Rifkin (Rocky Mountain Cancer Center, Denver, USA) chairs an expert panel discussion with Prof Lonial (Emory Cancer Institute, Atlanta, USA), Dr Smith (Dana-Farber Cancer Institute, Boston, USA), Prof Terpos (University of Athens, Athens, Greece) and Dr Shah (University of California, San Francisco, USA) on the latest in relapsed/refractory multiple myeloma with emphasis on immunotherapy.

They discuss all the updates from this year’s ASH conference regarding immunotherapies and CAR-T cell therapies for R/R multiple myeloma including the DREAMM, Karmma, Apollo, CARTITUDE and LUMMICAR trials.

Dr Rifkin highlights the key recent developments in the use of immunotherapy to treat relapsed or refractory MM and their impact on the latest understanding of best clinical practice which is then further discussed by the rest of the panel.

They further describe which agents are available in this area and how to identify the most appropriate treatment for each individual patient.

Prof Lonial and Terpos speak of the clinical trials landscape and how future data and approvals are expected to influence treatment strategies.

Dr Shah speaks about the results of Karmma trial. Further discussion on all the updates from this year’s ASH conference regarding immunotherapies for relapsed/refractory multiple myeloma is also carried out.

Dr Smith speaks about the future of CAR-T cell therapies in terms of clinical care and research and talks about talqutamab as a potential R/R multiple myeloma treatment drug.

This programme has been supported by an unrestricted educational grant from GSK.